Episode Details

NanoViricides CEO Dr Anil Diwan joined Steve Darling from Proactive to announce that the company has filed an application for Rare Pediatric Disease Drug Designation with the U.S. FDA’s Office of Orphan Products Development for NV-387 as a treatment for measles. The RPDD application is expected to be combined with the company’s previously submitted Orphan Drug Designation application for NV-387, filed in February 2026, as part of a broader regulatory strategy to advance the drug candidate. If granted, the designation would make NanoViricides eligible for a Priority Review Voucher upon approval of NV-387. PRVs are tradable assets that have recently commanded values of approximately $160 million, reflecting their ability to accelerate regulatory review timelines for other drugs. Diwan emphasized the potential impact of NV-387, stating the therapy could become an important tool in addressing the resurgence of measles in the United States and globally. He added that treatment with NV-387 may support rapid recovery while helping to reduce complications, including the rare but serious post-measles “immune amnesia” effect. Currently, there are no approved antiviral treatments specifically for measles, highlighting a significant unmet medical need. The Rare Pediatric Disease Priority Review Voucher program was reauthorized in February 2026 under the Consolidated Appropriations Act, reinforcing incentives for companies developing therapies targeting serious pediatric conditions. Measles cases have been rising in the United States, with more than 1,600 laboratory-confirmed cases reported across 33 states as of early April 2026, according to the CDC. While hospitalization rates have declined compared to 2025, the disease continues to pose risks, particularly among pediatric populations, which account for approximately 70% of cases. #proactiveinvestors #nanoviricidesinc #nyseamerican #nnvc #measles #nanoviricides #NV387 #OrphanDrugDesignation #AntiviralTherapy #ClinicalTrials #PhaseII #OrphanDrugDesignation #FDA #Measles #Antiviral #HealthcareInnovation #MedicalResearch #Biopharma #PediatricHealth #GlobalHealth